HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells (Tregs) function, today announced its financial results for fiscal year ended December 31, 2022, and provided a clinical and business update. FY 2022 and Early 2023 Highlights In March 2023, the Company announced positive results from a proof-of-concept, open-label academic cl My Business Wire News
